Barker headshot

Professor Roger Barker

Parkinson's and Huntington's disease


Laboratory Location:

John van Geest Centre for Brain Repair, Cambridge Biomedical Campus

Departmental Affiliation:

Department of Clinical Neurosciences


Roger Barker is the Professor of Clinical Neuroscience and Honorary Consultant in Neurology at the University of Cambridge and at Addenbrooke's Hospital.  He trained at Oxford and London and has been in his current position since 2000, after completing a MRC Clinician Scientist Fellowship.  

Roger combines basic research looking at novel therapies to treat chronic neurodegenerative disorders of the brain with clinically-based work aimed at better defining such disorders. He is the co-ordinator of the FP7 TRANSEURO project looking at fetal cell grafting in patients with early Parkinson's Disease.


• BA, Oxford University, 1983
• MBBS, University of London, 1986
• MRCP (London) 1989
• PhD, University of Cambridge, 1994


Birax, Parkinson's UK, MRC, BBSRC, EU-FP7, NIHR, Swedish MRC, Cotswold Trust

External links

Barker research image 2-1ratio
Dopaminergic neurons generated from human embryonic stem cells using a clinical grade protocol. Tyrosine hydroxylase, one of the characteristic markers of dopaminergic neurons, is shown in green with the axons and dendrites of the neurons demonstrated in red using beta-tubulin III immunostaining.


Our main interests are in the common, chronic neurodegenerative disorders of the nervous system in particular Parkinson's disease (PD) and Huntington's disease (HD).

We are interested in better understanding how these diseases develop and then how they change over time with the idea of better classifying patients into different subtypes of disease. These subtypes can then be used to test new therapies as some types of these diseases may be better suited for one type of experimental treatment whilst others may not: e.g. dopamine cell therapies from stem cells treatment may be better suited to younger PD patients with a more benign clinical course. 

In addition this ability to stratify patients also enables us to undertake studies looking at the how these disease subtypes may arise using cells grown from the patients themselves. Typically we harvest these cells from the skin and then turn them into nerve cells in the lab, and by so doing we hope that we can recapitulate what goes wrong in the brain nerve cells in such patients.

Barker group 2-1ratio

Philipp Berg

Nick Blair

Lucy Collins

Danielle Daft

Michelle Evans

Anna Gerritz

Nushan Gunawardana

Natalie V. Guzman

Katie Hall

Kate Harris

Shaista Hayat

Xiaoling He

Wei-Li Kuan

Alpar Lazar

Sarah Mason

Kirsten Scott

Simon Stott

Laetitia Schwab

Pam Tyers

Ruwani Wijeyekoon

Lindsey Wilkin

Caroline Williams Gray

Romina Vuono

Plain English

Our research primarily focuses on neurodegenerative disorders of the brain such as Parkinson’s disease (PD) and Huntington’s disease (HD). We have sought to better define the true extent of clinical deficits in these disorders, with the aim of building a more complete model of disease heterogeneity and its basis which will then serve to inform the translation of stem cell therapies to clinics by targeting the right sub-group of patients at the optimal stage of disease. 

Key Publications



Web design by Studio 24 / Back to top